PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27034161-3 2016 More recently, RET over-expression has emerged as a new player in ER-positive (ER+) BC, and as a potential target to enhance sensitivity and avoid resistance to tamoxifen therapy.Therefore, targeting the RET pathway may lead to new therapies in ER+ BC. Tamoxifen 161-170 ret proto-oncogene Homo sapiens 15-18 27034161-3 2016 More recently, RET over-expression has emerged as a new player in ER-positive (ER+) BC, and as a potential target to enhance sensitivity and avoid resistance to tamoxifen therapy.Therefore, targeting the RET pathway may lead to new therapies in ER+ BC. Tamoxifen 161-170 ret proto-oncogene Homo sapiens 204-207 24526731-10 2014 CONCLUSIONS: Vandetanib potentiated the antigrowth effects of tamoxifen in breast cancer, which was mediated through RET activation. Tamoxifen 62-71 ret proto-oncogene Homo sapiens 117-120 25409876-9 2014 In MCF7 cells, SPP86 inhibited RET- induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling and estrogen receptoralpha (ERalpha) phosphorylation, and inhibited proliferation to a similar degree as tamoxifen. Tamoxifen 211-220 ret proto-oncogene Homo sapiens 31-34 24045439-11 2014 Parallel experiments using treatment with tamoxifen and sunitinib confirmed the increased effectiveness of dual inhibition of the ER and RET pathways in regulating cell growth. Tamoxifen 42-51 ret proto-oncogene Homo sapiens 137-140 21737465-1 2011 RET, a gene causatively mutated in Hirschsprung disease and cancer, has recently been implicated in breast cancer estrogen (E2) independence and tamoxifen resistance. Tamoxifen 145-154 ret proto-oncogene Homo sapiens 0-3 24563328-3 2014 The expression analysis of selected genes involved in tamoxifen/estrogen and receptor tyrosine kinase signaling pathways can help to further decipher mechanisms of recurrence in ER+ tumors and contribute to the development of prognostic and possibly predictive biomarkers. Tamoxifen 54-63 ret proto-oncogene Homo sapiens 77-101 20531297-0 2010 Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Tamoxifen 77-86 ret proto-oncogene Homo sapiens 39-42 20531297-5 2010 In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug. Tamoxifen 3-12 ret proto-oncogene Homo sapiens 35-38 20531297-5 2010 In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug. Tamoxifen 145-154 ret proto-oncogene Homo sapiens 35-38 20531297-6 2010 In tamoxifen-resistant (TAM(R)-1) MCF7 cells, targeting RET restored tamoxifen sensitivity. Tamoxifen 3-12 ret proto-oncogene Homo sapiens 56-59 20531297-6 2010 In tamoxifen-resistant (TAM(R)-1) MCF7 cells, targeting RET restored tamoxifen sensitivity. Tamoxifen 69-78 ret proto-oncogene Homo sapiens 56-59 20531297-7 2010 Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ERalpha-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of RET-positive tumors. Tamoxifen 292-301 ret proto-oncogene Homo sapiens 119-122 20531297-7 2010 Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ERalpha-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of RET-positive tumors. Tamoxifen 292-301 ret proto-oncogene Homo sapiens 359-362 20531297-8 2010 Together these findings identify RET as a potentially important therapeutic target in ERalpha-positive breast cancers and in particular in tamoxifen-resistant tumors. Tamoxifen 139-148 ret proto-oncogene Homo sapiens 33-36 20689759-0 2010 Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Tamoxifen 62-71 ret proto-oncogene Homo sapiens 4-28 20689759-9 2010 In summary, these results illustrate a novel connection between the Ron receptor tyrosine kinase and an important mechanism of tamoxifen resistance in breast cancer. Tamoxifen 127-136 ret proto-oncogene Homo sapiens 72-96